OptimizeRx Stockholders Approve Expansion and Elect Directors
Company Announcements

OptimizeRx Stockholders Approve Expansion and Elect Directors

The latest update is out from OptimizeRx (OPRX).

At OptimizeRx Corporation’s 2024 Annual Meeting, stockholders have given their nod to several key proposals, including the expansion of the company’s Equity Incentive Plan by an additional 1,950,000 shares. This strategic amendment aims to incentivize performance and attract talent by increasing the total available shares for awards to 4,450,000. The meeting also saw the election of six directors and the approval of executive compensation on an advisory basis. Additionally, UHY LLP has been reappointed as the independent auditor for the fiscal year 2024, reinforcing stockholders’ confidence in the company’s financial oversight.

See more data about OPRX stock on TipRanks’ Stock Analysis page.

Related Articles
Brian AndersonIs OPRX a Buy, Before Earnings?
TheFlyOptimizeRx continues to expand strategic relationship with pharma client
TheFlyOptimizeRx price target lowered to $14 from $17 at RBC Capital
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App